Where the money went: management itemizes the period's spending into named growth uses tied to business already live
The model's full reasoning — Q4 2021 call → NOWe need to determine if management gives a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and ties those to already-real business. The transcript shows management discussing investments in TV advertising, new product launch, partnerships, etc. They mention testing TV ads, launching a new commercial, investing in brand building, R&D for new NAD precursor, etc. They also mention partnerships like Sinopharm, H&H, Designs for Health, and that they expect contributions in 2022. However, the question asks if they tie the spending to business that is ALREADY REAL - actual orders, customers, contracts, volumes, openings, or activity already arriving or committed now. They mention that H&H is delayed, Sinopharm is finalizing plans, etc. They also mention that they are investing in marketing and brand awareness. But do they itemize specific uses and tie to real business? They mention the new TV commercial launching, but that's a hope for future sales. They mention the new product launch, but not yet in market. They mention partnerships that are in various stages. The spending on TV and marketing is for future growth, not tied to already-real business. They also mention that they are reducing spend in less efficient areas. The overall tone is that they are investing for growth, but the specific uses are not tied to already-committed revenue. They do mention that they have enough cash to fund growth, but the itemization is not concrete in terms of tying to real orders. They mention that they are seeing improvement in cost per acquisition, but that's not a tie to real business. The question asks for a concrete accounting of where the period's money went, itemizing specific growth-directed uses, and tying to already-real business. Management does mention specific uses: TV advertising, new product development, R&D for new precursor, partnerships. But the tie to already-real business is weak. For example, they say "we expect them to contribute to increased sales in 2022" but that's future. They also say "we are finalizing commercial plans" for Sinopharm. So the spending is for future growth, not for business already arriving.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
AES · Q1 2024 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES Management itemizes the period’s spending in two places. - Utilities: “our Q1 investment was up nearly 100% from last year, as a result of the new rate structures and investing to improve system resilience and customer experience.” - Renewables: “we have also added almost 600 meg awatts of new projects to our operating portfolio” and “we remain fully on track to add a total of 3.6 gigawatts of new capacity this year” with “92% of the major equipment already on site” for 2024 projects. Both uses are explicitly tied to already-signed backlog ( 12.7 GW signed contracts, 1.
GTES · Q4 2021 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES The transcript shows management itemizing specific growth-directed uses—targeted incremental capacity investments, material science, and innovation—explicitly tied to already-real business: record backlog, book-to-build above 1, strong order rates, and committed wins (e.g., Gogoro, EV platform). These are framed as 2021 spending that consumed profitability and cash flow in Q4, directly supporting demand already arriving rather than future hope. While some operational headwinds (COVID, materials) are noted, the capacity investments are presented as the visible cost of growth underway.
DAN · Q1 2017 → YESThe question is about whether management gives a concrete accounting of where the period's money and effort went, specifically for growth-directed uses tied to already real business. YES Management itemizes concrete uses of the period’s cash and effort: higher capital spending to convert the $175 million backlog (Super Duty, Toyota HiLux, Jeep Wrangler readiness), the $25 million trade-payable settlement tied to the USM acquisition that is already supplying Dana, the Brevini integration costs 8 % organic growth plus aftermarket recovery, and the start-up costs of the new Toledo facility and Hungary gear plant that are supporting committed customer programs already in motion.